首頁 > 市場調查報告書 > 製藥

糖尿病

市場調查報告書

商品編碼

1459635

全球糖尿病前期市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢和預測

Global Prediabetes Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年03月01日 | 出版商:

Value Market Research | 英文 134 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球糖尿病前期市場需求預計將從 2023 年的 2.024 億美元增至 2032 年的近 4.1208 億美元，2024-2032 年研究期間複合CAGR為 8.22%。

糖尿病前期是一種健康狀況，其特徵是血糖水平高於正常水平，但不足以歸類為第 2 型糖尿病。如果不及時治療，糖尿病前期患者罹患糖尿病、心臟病和中風的風險更高。規律運動、營養飲食習慣和體重管理等生活方式的改變有助於延緩或預防第 2 型糖尿病的進展。定期監測血糖值和篩檢其他危險因子對於早期發現和介入至關重要。

市場動態

糖尿病前期市場受到多種因素的影響，包括糖尿病前期盛行率的上升、糖尿病預防意識的增強以及促進早期介入和生活方式改變的措施。糖尿病前期是糖尿病和心血管疾病發生的重要危險因子。隨著全球糖尿病負擔達到流行病的程度，人們越來越認知到糖尿病前期是一個重要的公共衛生問題，這推動了識別高風險族群並實施預防措施的努力。此外，宣傳活動、社區為基礎的糖尿病預防計劃和工作場所健康措施提高了公眾對健康生活方式選擇在預防糖尿病和減輕疾病負擔方面重要性的認知。此外，診斷技術和風險評估工具的進步使醫療保健提供者能夠及早識別糖尿病前期患者並實施個人化干涉措施以減緩疾病進展。此外，醫療保健組織、政府機構和非營利組織之間的合作支持實施針對糖尿病前期危險因子（例如肥胖、久坐生活方式和不健康飲食）的循證干預措施。然而，生活方式的改變導致糖尿病前期盛行率增加、醫療保健成本上升以及獲得預防性護理服務的機會有限，可能會阻礙市場成長。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球糖尿病前期市場的各個細分市場進行了包容性評估。糖尿病前期產業的成長和趨勢為本研究提供了整體方法。

市場區隔

糖尿病前期市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人群以及即將到來的機會。

按藥物類別

雙胍
噻唑烷二酮類
胰高血糖素樣胜肽-1 激動劑 (GLP-1)
SGLT2 抑制劑
DPP-4 抑制劑
其他

按年齡段

兒童（12-18 歲）
成人（18-49）
老年人（50歲以上）

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲糖尿病前期市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。糖尿病前期市場的主要參與者包括諾和諾德、Valbiotis、Resverlogix、Caelus Health、SciMar、Boston Therapeutics、Aphaia Pharma、阿斯特捷利康、百時美施貴寶。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區國家/地區銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 8 章：糖尿病前期公司的競爭格局

糖尿病前期市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 9 章：公司簡介

頂級公司市佔率分析
市場集中度
Novo Nordisk

公司簡介
公司收入
產品
最近的發展

Valbiotis

公司簡介
公司收入
產品
最近的發展

Resverlogix

公司簡介
公司收入
產品
最近的發展

Caelus Health

公司簡介
公司收入
產品
最近的發展

SciMar

公司簡介
公司收入
產品
最近的發展

Boston Therapeutics

公司簡介
公司收入
產品
最近的發展

Aphaia Pharma

公司簡介
公司收入
產品
最近的發展

AstraZeneca

公司簡介
公司收入
產品
最近的發展

Bristol-Myers Squibb

公司簡介
公司收入
產品
最近的發展

注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私人公司，則可能不包括在內

簡介目錄圖表

Product Code: VMR112114025

The global demand for Prediabetes Market is presumed to reach the market size of nearly USD 412.08 Million by 2032 from USD 202.4 Million in 2023 with a CAGR of 8.22% under the study period 2024 - 2032.

Prediabetes is a health condition featured by elevated blood sugar levels that exceed usual but are not great enough to be classified as type 2 diabetes. Individuals with prediabetes are at a higher risk of developing diabetes, heart disease, & stroke if left untreated. Lifestyle modifications such as regular exercise, nutritious dietary habits, and weight management can help delay or prevent the progression of type 2 diabetes. Regular monitoring of blood sugar levels and screening for other risk factors are crucial for early detection and intervention.

MARKET DYNAMICS

The prediabetes market is influenced by several factors, including the rising prevalence of prediabetes, increasing awareness about diabetes prevention, and initiatives promoting early intervention and lifestyle modifications. Prediabetes poses a significant risk factor for the development of diabetes and cardiovascular diseases. With the global burden of diabetes reaching epidemic proportions, there is growing recognition of prediabetes as a critical public health concern, driving efforts to identify at-risk individuals and implement preventive measures. Moreover, awareness campaigns, community-based diabetes prevention programs, and workplace wellness initiatives raise public awareness about the importance of healthy lifestyle choices in preventing diabetes and reducing disease burden. Additionally, advancements in diagnostic technologies and risk assessment tools enable healthcare providers to identify individuals with prediabetes early and implement personalized interventions to mitigate disease progression. Furthermore, collaborations between healthcare organizations, government agencies, and non-profit organizations support the implementation of evidence-based interventions targeting prediabetes risk factors, such as obesity, sedentary lifestyle, and unhealthy diet. However, lifestyle changes leading to increased prevalence of prediabetes, rising healthcare costs, and limited access to preventive care services may impede market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of prediabetes. The growth and trends of prediabetes industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the prediabetes market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

Diguanide
Thiazolidinediones
Glucagon-Like Peptide-1 Agonists (GLP-1)
SGLT2 Inhibitors
DPP-4 Inhibitors
Others

By Age Group

Children (12-18 Years)
Adults (18-49)
Elderly (50+)

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Prediabetes market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Prediabetes market include Novo Nordisk, Valbiotis, Resverlogix, Caelus Health, SciMar, Boston Therapeutics, Aphaia Pharma, AstraZeneca, Bristol-Myers Squibb. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . PREDIABETES - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Class
- 3.7.2 Market Attractiveness Analysis By Age Group
- 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL PREDIABETES MARKET ANALYSIS BY DRUG CLASS

5.1 Overview by Drug Class
5.2 Historical and Forecast Data
5.3 Analysis by Drug Class
5.4 Diguanide Historic and Forecast Sales by Regions
5.5 Thiazolidinediones Historic and Forecast Sales by Regions
5.6 Glucagon-Like Peptide-1 Agonists (GLP-1) Historic and Forecast Sales by Regions
5.7 SGLT2 Inhibitors Historic and Forecast Sales by Regions
5.8 DPP-4 Inhibitors Historic and Forecast Sales by Regions
5.9 Others Historic and Forecast Sales by Regions

6 . GLOBAL PREDIABETES MARKET ANALYSIS BY AGE GROUP

6.1 Overview by Age Group
6.2 Historical and Forecast Data
6.3 Analysis by Age Group
6.4 Children (12-18 Years) Historic and Forecast Sales by Regions
6.5 Adults (18-49) Historic and Forecast Sales by Regions
6.6 Elderly (50+) Historic and Forecast Sales by Regions

7 . GLOBAL PREDIABETES MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1. Overview, Historic and Forecast Data Sales Analysis
- 7.3.2. North America By Segment Sales Analysis
- 7.3.3. North America By Country Sales Analysis
- 7.3.4. United State Sales Analysis
- 7.3.5. Canada Sales Analysis
- 7.3.6. Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1. Overview, Historic and Forecast Data Sales Analysis
- 7.4.2. Europe by Segment Sales Analysis
- 7.4.3. Europe by Country Sales Analysis
- 7.4.4. United Kingdom Sales Analysis
- 7.4.5. France Sales Analysis
- 7.4.6. Germany Sales Analysis
- 7.4.7. Italy Sales Analysis
- 7.4.8. Russia Sales Analysis
- 7.4.9. Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1. Overview, Historic and Forecast Data Sales Analysis
- 7.5.2. Asia Pacific by Segment Sales Analysis
- 7.5.3. Asia Pacific by Country Sales Analysis
- 7.5.4. China Sales Analysis
- 7.5.5. India Sales Analysis
- 7.5.6. Japan Sales Analysis
- 7.5.7. South Korea Sales Analysis
- 7.5.8. Australia Sales Analysis
- 7.5.9. South East Asia Sales Analysis
- 7.5.10. Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1. Overview, Historic and Forecast Data Sales Analysis
- 7.6.2. Latin America by Segment Sales Analysis
- 7.6.3. Latin America by Country Sales Analysis
- 7.6.4. Brazil Sales Analysis
- 7.6.5. Argentina Sales Analysis
- 7.6.6. Peru Sales Analysis
- 7.6.7. Chile Sales Analysis
- 7.6.8. Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1. Overview, Historic and Forecast Data Sales Analysis
- 7.7.2. Middle East & Africa by Segment Sales Analysis
- 7.7.3. Middle East & Africa by Country Sales Analysis
- 7.7.4. Saudi Arabia Sales Analysis
- 7.7.5. UAE Sales Analysis
- 7.7.6. Israel Sales Analysis
- 7.7.7. South Africa Sales Analysis
- 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE PREDIABETES COMPANIES

8.1. Prediabetes Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9 . COMPANY PROFILES OF PREDIABETES INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Novo Nordisk
- 9.3.1. Company Overview
- 9.3.2. Company Revenue
- 9.3.3. Products
- 9.3.4. Recent Developments
9.4. Valbiotis
- 9.4.1. Company Overview
- 9.4.2. Company Revenue
- 9.4.3. Products
- 9.4.4. Recent Developments
9.5. Resverlogix
- 9.5.1. Company Overview
- 9.5.2. Company Revenue
- 9.5.3. Products
- 9.5.4. Recent Developments
9.6. Caelus Health
- 9.6.1. Company Overview
- 9.6.2. Company Revenue
- 9.6.3. Products
- 9.6.4. Recent Developments
9.7. SciMar
- 9.7.1. Company Overview
- 9.7.2. Company Revenue
- 9.7.3. Products
- 9.7.4. Recent Developments
9.8. Boston Therapeutics
- 9.8.1. Company Overview
- 9.8.2. Company Revenue
- 9.8.3. Products
- 9.8.4. Recent Developments
9.9. Aphaia Pharma
- 9.9.1. Company Overview
- 9.9.2. Company Revenue
- 9.9.3. Products
- 9.9.4. Recent Developments
9.10. AstraZeneca
- 9.10.1. Company Overview
- 9.10.2. Company Revenue
- 9.10.3. Products
- 9.10.4. Recent Developments
9.11. Bristol-Myers Squibb
- 9.11.1. Company Overview
- 9.11.2. Company Revenue
- 9.11.3. Products
- 9.11.4. Recent Developments